137 related articles for article (PubMed ID: 26290848)
1. Comparison of the Efficacy of Two Brands of Triptorelin (Microrelin and Diphereline) in Reducing Prostate-Specific Antigen and Serum Testosterone in Prostate Cancer: A Double-Blinded Randomized Clinical Trial.
Fazeli F; Nowroozi MR; Ayati M; Latifi S; Taheri Mahmoodi M; Norouzi Javidan A; Jamshidian H; Arbab A
Nephrourol Mon; 2015 May; 7(3):e27107. PubMed ID: 26290848
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of diphereline 11.25 mg, microrelin 11.25 mg, and microrelin 3.75 mg in premenopausal patients with breast cancer: a non-inferiority randomized clinical trial.
Najafi S; Ansari M; Omidi Z; Olfatbakhsh A; Moghadam S; Hashemi EO; Najafi N; Haghighat S
BMC Cancer; 2023 Nov; 23(1):1093. PubMed ID: 37950162
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer.
Lebret T; Rouanne M; Hublarov O; Jinga V; Petkova L; Kotsev R; Sinescu I; Dutailly P
Ther Adv Urol; 2015 Jun; 7(3):125-34. PubMed ID: 26161143
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.
Breul J; Lundström E; Purcea D; Venetz WP; Cabri P; Dutailly P; Goldfischer ER
Adv Ther; 2017 Feb; 34(2):513-523. PubMed ID: 28028737
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
Heyns CF; Simonin MP; Grosgurin P; Schall R; Porchet HC;
BJU Int; 2003 Aug; 92(3):226-31. PubMed ID: 12887472
[TBL] [Abstract][Full Text] [Related]
7. Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.
Østergren PB; Kistorp C; Fode M; Henderson J; Bennedbæk FN; Faber J; Sønksen J
J Urol; 2017 Jun; 197(6):1441-1447. PubMed ID: 27939836
[TBL] [Abstract][Full Text] [Related]
8. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
11. Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient-Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study.
Cornford P; Jefferson K; Cole O; Gilbody J
Oncol Ther; 2018 Dec; 6(2):173-187. PubMed ID: 32700031
[TBL] [Abstract][Full Text] [Related]
12. A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer.
Kuhn JM; Abourachid H; Brucher P; Doutres JC; Fretin J; Jaupitre A; Jorest R; Lambert D; Petit J; Pin J; Blumberg J; Dufour-Esquerré F
Eur Urol; 1997; 32(4):397-403. PubMed ID: 9412795
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of long-acting gonadotropin-releasing hormone analogue in the treatment for metastatic prostate cancer].
Li NC; Song Y; Jiang HW; Ding Q; Gan WD; Guo HQ; Sun ZY; Hu ZQ; Ye ZQ; Wei Q; Na YQ
Zhonghua Wai Ke Za Zhi; 2008 Nov; 46(21):1653-7. PubMed ID: 19094763
[TBL] [Abstract][Full Text] [Related]
14. A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer.
Gil T; Aoun F; Cabri P; Maisonobe P; van Velthoven R
Ther Adv Urol; 2015 Jun; 7(3):116-24. PubMed ID: 26161142
[TBL] [Abstract][Full Text] [Related]
15. Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies.
Klotz L; Tat T
BJUI Compass; 2024 Mar; 5(3):392-402. PubMed ID: 38481666
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of the effect of testosterone escape on preradiotherapy prostate-specific antigen kinetics in prostate cancer patients undergoing neoadjuvant androgen deprivation therapy.
Christie DRH; Mitina N; Sharpley CF
Curr Urol; 2021 Mar; 15(1):63-67. PubMed ID: 34084124
[TBL] [Abstract][Full Text] [Related]
17. Triptorelin in the management of prostate cancer.
Ploussard G; Mongiat-Artus P
Future Oncol; 2013 Jan; 9(1):93-102. PubMed ID: 23252566
[TBL] [Abstract][Full Text] [Related]
18. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Steinberg M
Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
[TBL] [Abstract][Full Text] [Related]
19. An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.
Merseburger AS; Hupe MC
Adv Ther; 2016 Jul; 33(7):1072-93. PubMed ID: 27246172
[TBL] [Abstract][Full Text] [Related]
20. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer.
Van Poppel H; Tombal B; de la Rosette JJ; Persson BE; Jensen JK; Kold Olesen T
Eur Urol; 2008 Oct; 54(4):805-13. PubMed ID: 18538469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
